BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers. HEIDLEBERG, GERMANY / ACCESSWIRE / April 4, 2023 / BioMed X, an independent biomedical research institute, announces the start of its new research project – “New Strategies to Enhance the Immunogenicity […]